In our study, the incidence of grade 4 CIN in the first cycle was comparable with a previous study in Indonesia without G-CSF prophylaxis (30.6% versus 27.4%) [15], although we included all stage I–IV patients and not only those receiving adjuvant chemotherapy as it did. The gene discussed is CSF3; the disease is cervical squamous intraepithelial neoplasia.